Paper Details 
Original Abstract of the Article :
Despite appropriate medical therapy, many horses with equine recurrent uveitis continue to suffer from recurrent bouts of inflammation. Surgical intervention via the pars plana vitrectomy or suprachoroidal cyclosporine implant placement may control and/or prevent recurrences, however, these procedur...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335700/

データ提供:米国国立医学図書館(NLM)

Intravitreal Gentamicin: A Potential Adjunctive Treatment for Recurrent Equine Uveitis

Equine recurrent uveitis (ERU), a debilitating eye condition affecting horses, can lead to vision loss and significant discomfort. This study investigates the potential of intravitreal gentamicin injections as an adjunctive treatment for ERU. Researchers conducted a prospective study involving 86 horses presenting with recurrent or persistent uveitis, treating them with intravitreal injections of gentamicin.

Intravitreal Gentamicin: A Promising Adjunctive Treatment for ERU

The study found that intravitreal gentamicin injections were generally safe, with minimal complications. Furthermore, the treatment appeared to be effective in controlling clinical signs of uveitis in a significant proportion of horses.

A Desert Oasis for Horses with ERU

Imagine a desert with shimmering oases, providing much-needed relief for thirsty travelers. Intravitreal gentamicin, like a refreshing oasis, can offer valuable relief for horses suffering from ERU, potentially improving their vision and quality of life.

Dr. Camel's Conclusion

This study provides preliminary evidence for the potential of intravitreal gentamicin as a safe and effective adjunctive treatment option for ERU. Further research is needed to establish the long-term efficacy and optimal dosing regimen for this treatment approach.

Date :
  1. Date Completed 2019-01-22
  2. Date Revised 2020-02-25
Further Info :

Pubmed ID

30651102

DOI: Digital Object Identifier

PMC6335700

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.